Payment overview · 2025
General Payments
$1,361.14
87 reported records · 20 companies
Healthcare provider profile · identity verified
Benjamin S Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · HARDINSBURG, KY · NPI 1366445108
Verified facts
What the public records show
CMS Open Payments records show Benjamin S Smith, MD received $1,361.14 in general payments during 2025 across 87 reported records.
Novo Nordisk Inc accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $286.57 | 21.1% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $159.98 | 11.8% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.86 | 10.6% | 11 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $97.64 | 7.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $93.09 | 6.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.06 | 6.0% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $70.00 | 5.1% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $63.05 | 4.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.63 | 4.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.37 | 3.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.08 | 3.3% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.63 | 3.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.44 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.89 | 2.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.68 | 1.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.41 | 1.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.98 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.94 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.74 | 1.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.10 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,361.14 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $220.84 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $220.84 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $144.59 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $97.64 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $93.09 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76.80 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.71 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $70.00 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $67.06 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.38 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.73 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $65.11 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $63.05 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $57.63 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $51.38 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.89 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.89 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.08 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.89 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 31 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 361 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 308 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 140 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
113 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
308 | 44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
361 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
140 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
308 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
361 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 827 | 174 |
| Furosemide | Furosemide | 736 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 674 | 159 |
| Metoprolol Succinate | Metoprolol Succinate | 652 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 592 | 148 |
| Gabapentin | Gabapentin | 580 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 106 |
| Sertraline Hcl | Sertraline Hcl | 539 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 492 | 79 |
| Potassium Chloride | Potassium Chloride | 405 | 79 |
| Losartan Potassium | Losartan Potassium | 375 | 92 |
| Omeprazole | Omeprazole | 373 | 97 |
| Eliquis | Apixaban | 361 | 51 |
| Lisinopril | Lisinopril | 349 | 84 |
| Montelukast Sodium | Montelukast Sodium | 344 | 73 |
| Trazodone Hcl | Trazodone Hcl | 344 | 73 |
| Jardiance | Empagliflozin | 308 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 288 | 94 |
| Valsartan | Valsartan | 282 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 74 |
| Metformin Hcl | Metformin Hcl | 271 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 267 | 62 |
| Famotidine | Famotidine | 266 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 265 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 75 |
| Meloxicam | Meloxicam | 257 | 56 |
| Alprazolam | Alprazolam | 256 | 31 |
| Carvedilol | Carvedilol | 255 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 254 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 52 |
| Buspirone Hcl | Buspirone Hcl | 229 | 34 |
| Mirtazapine | Mirtazapine | 229 | 51 |
| Tramadol Hcl | Tramadol Hcl | 224 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 222 | 37 |
| Xarelto | Rivaroxaban | 210 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 205 | 47 |
| Ondansetron Hcl | Ondansetron Hcl | 200 | 73 |
| Spironolactone | Spironolactone | 196 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 194 | 43 |
| Colestipol Hcl | Colestipol Hcl | 190 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 174 | 126 |
| Memantine Hcl | Memantine Hcl | 170 | 37 |
| Sucralfate | Sucralfate | 163 | 35 |
| Lorazepam | Lorazepam | 157 | 30 |
| Nystatin | Nystatin | 148 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 22 |
| Donepezil Hcl | Donepezil Hcl | 145 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 145 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 140 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 136 | 27 |
| Prednisone | Prednisone | 135 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 133 | 30 |
| Ozempic | Semaglutide | 132 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 131 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 35 |
| Risperidone | Risperidone | 123 | 25 |
| Clonazepam | Clonazepam | 120 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 21 |
| Divalproex Sodium | Divalproex Sodium | 118 | 22 |
| Ezetimibe | Ezetimibe | 118 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 23 |
| Fluconazole | Fluconazole | 114 | 64 |
| Metformin Hcl Er | Metformin Hcl | 114 | 25 |
| Pregabalin | Pregabalin | 114 | 21 |
| Synthroid | Levothyroxine Sodium | 113 | 24 |
| Allopurinol | Allopurinol | 112 | 31 |
| Bupropion Xl | Bupropion Hcl | 112 | 24 |
| Ibuprofen | Ibuprofen | 111 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 107 | 22 |
| Alendronate Sodium | Alendronate Sodium | 106 | 13 |
| Loperamide | Loperamide Hcl | 104 | 48 |
| Mupirocin | Mupirocin | 104 | 48 |
| Aripiprazole | Aripiprazole | 103 | 18 |
| Simvastatin | Simvastatin | 103 | 21 |
| Levetiracetam | Levetiracetam | 101 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 39 |
| Cephalexin | Cephalexin | 97 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 24 |
| Promethazine Hcl | Promethazine Hcl | 97 | 29 |
| Ibandronate Sodium | Ibandronate Sodium | 95 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 16 |
| Baclofen | Baclofen | 92 | 30 |
| Levofloxacin | Levofloxacin | 92 | 48 |
| Oxycodone Hcl | Oxycodone Hcl | 87 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 51 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 86 | 20 |
| Dexamethasone | Dexamethasone | 86 | 67 |
| Divalproex Sodium Er | Divalproex Sodium | 86 | 12 |
| Topiramate | Topiramate | 86 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 14 |
| Atenolol | Atenolol | 80 | 16 |
| Estradiol | Estradiol | 79 | 23 |
| Finasteride | Finasteride | 75 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 18 |
| Warfarin Sodium | Warfarin Sodium | 72 | 13 |
| Farxiga | Dapagliflozin Propanediol | 71 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 20 |
| Olanzapine | Olanzapine | 68 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 12 |
| Meclizine Hcl | Meclizine Hcl | 66 | 12 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 11 |
| Celecoxib | Celecoxib | 61 | 19 |
| Azithromycin | Azithromycin | 60 | 43 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Ondansetron Odt | Ondansetron | 60 | 40 |
| Midodrine Hcl | Midodrine Hcl | 59 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 59 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 57 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 36 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 15 |
| Diazepam | Diazepam | 55 | 12 |
| Movantik | Naloxegol Oxalate | 54 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 54 | 13 |
| Amoxicillin | Amoxicillin | 53 | 46 |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | 13 |
| Myrbetriq | Mirabegron | 53 | 11 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 49 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Nitroglycerin | Nitroglycerin | 48 | 32 |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 46 | suppressed |
| Colchicine | Colchicine | 45 | 15 |
| Fentanyl | Fentanyl | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 12 |
| Nystop | Nystatin | 43 | 23 |
| Digoxin | Digoxin | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | 11 |
| Lansoprazole | Lansoprazole | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Ketoconazole | Ketoconazole | 41 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 40 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Cefdinir | Cefdinir | 37 | 33 |
| Lactulose | Lactulose | 37 | 15 |
| Levemir Flexpen | Insulin Detemir | 37 | suppressed |
| Febuxostat | Febuxostat | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 24 |
| Clotrimazole | Clotrimazole | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 11 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 11 |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 27 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 17 |
| Budesonide | Budesonide | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 23 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 18 |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Fluorouracil | Fluorouracil | 21 | 19 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Multaq | Dronedarone Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | 11 |
| Valproic Acid | Valproic Acid | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 17 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Ssd | Silver Sulfadiazine | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 15 |
| Ofloxacin | Ofloxacin | 15 | 12 |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | 12 |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Dronabinol | Dronabinol | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | 11 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bumetanide | Bumetanide | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,361.14 · 87 records | Novo Nordisk Inc | ABRYSVO, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, DUPIXENT, ELIQUIS, EVENITY, JARDIANCE, Kerendia, Korlym, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tymlos, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error